Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lori Shafner"'
Autor:
Robert A. Brodsky, Régis Peffault de Latour, Scott T. Rottinghaus, Alexander Röth, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen, Jaroslaw P. Maciejewski, Jeff Szer, Jong Wook Lee, Austin G. Kulasekararaj, Lori Volles, Andrew I. Damokosh, Stephan Ortiz, Lori Shafner, Peng Liu, Anita Hill, Hubert Schrezenmeier
Publikováno v:
Haematologica, Vol 106, Iss 1 (2020)
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab. Ravulizumab, a new long-acting C5 inhibitor with
Externí odkaz:
https://doaj.org/article/e3c0bd580d374332a80ee7518eb29f3a
Autor:
Lori Shafner, Lori Volles, Flore Sicre de Fontbrune, Rasha Aguzzi, Viviani Pessoa, Anita J. Hill, Hubert Schrezenmeier, Lily Wong Lee Lee, Vadim Ptushkin, Rajendra Pradhan, Sandra Fátima Menosi Gualandro, Jong Wook Lee, Scott T. Rottinghaus, Wolfgang Füreder
Publikováno v:
Blood. 133:530-539
Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor–naive adults with paro
Autor:
Régis Peffault de Latour, Lori Shafner, Peter Hillmen, Lori Volles, Robert A. Brodsky, Antonio M. Risitano, Ilene C. Weitz, Hubert Schrezenmeier, Andrew I. Damokosh, Jeff Szer, Peng Liu, Anita Hill, Scott T. Rottinghaus, Austin G. Kulasekararaj, Jong Wook Lee, Stephan Ortiz, Alexander Röth, Jaroslaw P. Maciejewski
Publikováno v:
Haematologica
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab. Ravulizumab, a new long-acting C5 inhibitor with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::137afc53b99c420bf188c5d4889af4e7
http://hdl.handle.net/11588/812188
http://hdl.handle.net/11588/812188
Autor:
L.W. Lee Lee, Lori Volles, Lori Shafner, F. Sicre de Fontbrune, Vadim Ptushkin, Scott T. Rottinghaus, Viviani Pessoa, Rajendra Pradhan, Anita J. Hill, Sandra Fátima Menosi Gualandro, Andrew I. Damokosh, Jong Wook Lee, Hubert Schrezenmeier, Wolfgang Füreder, Rasha Aguzzi, S. Ortis
Publikováno v:
Science meets clinical practice.
Autor:
Régis Peffault de Latour, Saskia Langemeijer, Anna Gaya, Lori Shafner, Scott T. Rottinghaus, Austin G. Kulasekararaj, Jeff Szer, Caroline I. Piatek, Stephan Ortiz, Emilio Ojeda Gutierrez, Anita J. Hill, Richard A. Wells, F. Ataulfo Gonzalez-Fernandez, Eric Bachman, Antonio M. Risitano, Andrew I. Damokosh, Jong Wook Lee, Shinji Nakao, Alexander Röth
Publikováno v:
Blood, 133, 6, pp. 540-549
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Blood, 133, 540-549
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Blood, 133, 540-549
Contains fulltext : 202845.pdf (Publisher’s version ) (Open Access) Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was noninferior to eculizumab administered every 2 weeks in complement-inhibitor-naive patients wit
Autor:
Alvaro Urbano-Ispizua, Hubert Schrezenmeier, Jong Wook Lee, Jin Seok Kim, Austin G. Kulasekararaj, Jun Ho Jang, Louis Terriou, Andrew I. Damokosh, Lori Shafner, Eric Bachman, Anita J. Hill, Rasha Aguzzi, Alexander Röth, Jeff Szer, Scott T. Rottinghaus, Richard A. Wells
Ravulizumab (ALXN1210), a humanized monoclonal antibody to complement component C5, was engineered from eculizumab to have a substantially longer terminal half-life, permitting longer dosing intervals for paroxysmal nocturnal hemoglobinuria (PNH) tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a63e7b808f134174155d22d0690a91fe
https://europepmc.org/articles/PMC6134221/
https://europepmc.org/articles/PMC6134221/
Autor:
F. Sicre de Fontbrune, Austin G. Kulasekararaj, Lindsay Mitchell, Richard A. Wells, Stephan Ortiz, Shinichiro Okamoto, Lori Shafner, Scott T. Rottinghaus, Gérard Socié, Jong Wook Lee, T. Devo, Hubert Schrezenmeier, Peng Liu
Publikováno v:
HemaSphere. 3:385-386
Autor:
Jong Wook Lee, Alexander Röth, Austin G. Kulasekararaj, Jaroslaw P. Maciejewski, Lori Volles, Antonio M. Risitano, Ilene C. Weitz, Peter Hillmen, Régis Peffault de Latour, Lori Shafner, Scott T. Rottinghaus, Anita J. Hill, Hubert Schrezenmeier, Robert A. Brodsky, Andrew I. Damokosh, Jeff Szer, Stephan Ortiz
Publikováno v:
Blood. 132:2330-2330
Background/Objective: Breakthrough hemolysis (BTH) is the return of hemolytic disease activity during treatment with complement C5 inhibitors for paroxysmal nocturnal hemoglobinuria (PNH). BTH may be associated with inadequate C5 inhibition or comple
Autor:
Lori Shafner, Anna Gaya, Austin G. Kulasekararaj, Jong Wook Lee, Antonio M. Risitano, Emilio Ojeda Gutierrez, Eric Bachman, F. Ataulfo Gonzalez-Fernandez, Caroline I. Piatek, Richard A. Wells, Shinji Nakao, Régis Peffault de Latour, Andrew I. Damokosh, Alexander Röth, Scott T. Rottinghaus, Jeff Szer, Saskia Langemeijer, Anita J. Hill, Stephan Ortiz
Publikováno v:
Blood. 132:625-625
Introduction Ravulizumab, an innovative complement C5 inhibitor given every 8 weeks (q8w), was recently demonstrated in a large phase 3 study of patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) and naïve to complement inhibitor therapy
Autor:
Jun Ho Jang, Lori Shafner, Eric Bachman, Jeff Szer, Rasha Aguzzi, Scott T. Rottinghaus, Jin Seok Kim, Jong Wook Lee
Publikováno v:
Blood. 128:2428-2428
Background: ALXN1210 is a humanized monoclonal antibody designed for rapid, complete, sustained inhibition of C5 with less frequent dosing. A previous study in healthy volunteers demonstrated immediate, complete, and sustained C5 inhibition. The term